Our data showed that majority of CD8+ TILs co-expressed PD-1 and LAG-3 (Figure 3F), which likely rendered CD8+ T cells incapable of mounting effective anti-tumor immune responses. The gene discussed is PDCD1; the disease is neoplasm.